00:08 , Jan 28, 2017 |  BioCentury  |  Finance

Spotlight on T1D

With a planned $80 million fund, JDRF aims to attract a wave of investment from VCs and strategic investors to early stage Type I diabetes companies. JDRF announced the first close of the JDRF T1D...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Financial News

AnTolRx completes venture financing

AnTolRx Inc. ,   Business: Endocrine/Metabolic, Autoimmune   Date completed: 2016-09-08   Type: Venture financing   Raised: $4 million   Investors: Pfizer Inc. ; Orion Equity Partners LLC; Juvenile Diabetes Research Foundation  ...
07:00 , Sep 8, 2016 |  BC Extra  |  Financial News

Pfizer, JDRF among newco AnTolRx's investors

Diabetes newco AnTolRx Inc. (Cambridge, Mass.) raised $4 million in a series A round led by Pfizer Inc. (NYSE:PFE). Orion Equity Partners and JDRF also participated. AnTolRx is developing nanoparticles that combine an antigen with...